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Background: Radiotherapy can be an effective treatment for prostate cancer, but radiorecurrent tumours do develop.
Considering prostate cancer heterogeneity, we hypothesised that primitive stem-like cells may constitute the radiation-resistant
fraction.
Methods: Primary cultures were derived from patients undergoing resection for prostate cancer or benign prostatic hyperplasia.
After short-term culture, three populations of cells were sorted, reflecting the prostate epithelial hierarchy, namely stem-like cells
(SCs, a2b1integrin
hi/CD133þ ), transit-amplifying (TA, a2b1integrin
hi/CD133 ) and committed basal (CB, a2b1integrin
lo) cells.
Radiosensitivity was measured by colony-forming efficiency (CFE) and DNA damage by comet assay and DNA damage foci
quantification. Immunofluorescence and flow cytometry were used to measure heterochromatin. The HDAC (histone deacetylase)
inhibitor Trichostatin A was used as a radiosensitiser.
Results: Stem-like cells had increased CFE post irradiation compared with the more differentiated cells (TA and CB). The SC
population sustained fewer lethal double-strand breaks than either TA or CB cells, which correlated with SCs being less
proliferative and having increased levels of heterochromatin. Finally, treatment with an HDAC inhibitor sensitised the SCs to
radiation.
Interpretation: Prostate SCs are more radioresistant than more differentiated cell populations. We suggest that the primitive cells
survive radiation therapy and that pre-treatment with HDAC inhibitors may sensitise this resistant fraction.
Precision radiotherapy (external beam or brachytherapy) is an
important treatment for localised prostate cancer. However,
despite improvements in targeting and dose, one-third of patients
still fail because of local or systemic resistance (Brawer, 2002;
Catton et al, 2003; Ishkanian et al, 2010). Metastases following
radiotherapy are a significant clinical problem that requires an
improved understanding of the biology of treatment-resistant
phenotypes (Zafarana and Bristow, 2010; Jones, 2011). The use of
in vitro cell line models of prostate cancer has demonstrated that
clones of radioresistant cells emerge post irradiation (Bromfield
et al, 2003; van Oorschot et al, 2013). There have also been
radiation response studies using normal prostate tissue and
primary cells from normal biopsies (Kiviharju-af Hallstrom et al,
2007; Jaamaa et al, 2010; Zhang et al, 2011). However, none of
these studies addressed the phenotype of the resistant clones. We,
and others, have shown that a cellular hierarchy exists in several
cancer types and in both prostate cancer epithelium and normal
prostate epithelium (Collins et al, 2001; Hudson et al, 2001;
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Miller et al, 2005; Visvader and Lindeman, 2008; Maitland et al, 2010;
Clevers, 2011). These studies demonstrated that the more stem-like
cells (SCs), at the beginning of the hierarchy, have more clonogenic
and tumourigenic potential than the more differentiated cells.
Moreover, in glioblastoma, it was demonstrated that the primitive
cells were more resistant to radiotherapy than the majority of cells
within the tumour (Bao et al, 2006). This finding has been backed
up by other studies suggesting that the SCs may be directly
responsible for tumour recurrence (Chiou et al, 2008; Diehn et al,
2009b; Conley et al, 2012; Chen et al, 2013). In light of these
findings, we hypothesised that the SCs in prostate cancer would be
more resistant to irradiation than the more differentiated
populations. Using the same markers we had previously used to
isolate the normal and malignant prostate hierarchy (Collins et al,
2001; Richardson et al, 2004; Collins et al, 2005), we show here that
the most undifferentiated cells in both benign and malignant
primary cultures are more resistant to irradiation. This resistance is
conferred by heterochromatin, which protects the cells from the
DNA-damaging effects of radiation.
MATERIALS AND METHODS
Tissue collection, isolation and culture of tumour cells. Human
prostate tissue was obtained with patient’s consent and full ethical
approval from patients undergoing radical prostatectomy and
channel transurethral resection (TURP) for prostate cancer and
from patients undergoing transurethral resection for benign
prostatic hyperplasia (BPH) (Table 1). Grade and stage of tumour
were confirmed by histologic examination of representative
fragments by a uropathologist. Epithelial cultures were prepared
and characterised as described previously (Collins et al, 2001). Cell
cultures were maintained in stem cell media (SCM) consisting of
Table 1. Patient samples
Sample Passage Operation Patient age Diagnosis Hormone status
Benign samples
B1 8þ5 C — Benign —
B2 5 T 58 Benign —
B3 5 T 77 Benign —
B4 4 T 88 Benign —
B5 2þ6 C 72 Benign —
B6 5 T 83 Benign —
B7 3 T 82 Benign —
B8 4 T 65 Benign —
B9 3 T 83 Benign —
B10 6 T 77 Benign —
B11 5 T 67 Benign —
B12 6 T 74 Benign —
B13 1 T — Benign —
B14 2 T 72 Benign —
B15 3 T 71 Benign —
B16 3 T 62 Benign —
B17 3 T 84 Benign —
B18 4 R 61 Benign —
Cancer samples
C1 3þ4 T 71 Cancer Gl6 (3þ3) Naive
C2 3 R 68 Cancer Gl6 (3þ3) Naive
C3 3 R 68 Cancer Gl6 (3þ3) Naive
C4 5þ6 R 62 Cancer Gl7 (3þ4) Naive
C5 10 R 53 Cancer Gl7 (3þ4) Naive
C6 3 R 65 Cancer Gl7 (3þ4) Naive
C7 2 R 70 Cancer Gl7 (3þ4) Naive
C8 4 R 64 Cancer Gl7 (3þ4) Naive
C9 4 R 64 Cancer Gl7 (3þ4) Naive
C10 6 R — Cancer Gl7 (4þ3) Naı¨ve
C11 3 R 58 Cancer Gl7 (3þ4) Naive
C12 6 R 47 Cancer Gl7 (4þ3) Naive
C13 8 R — Cancer Gl7 (3þ4) Naive
C14 9 R 66 Cancer Gl7 (3þ4) Naive
C15 4 R 70 Cancer Gl7 (3þ4) Naive
C16 4 R 70 Cancer Gl7 (3þ4) Naive
C17 3þ6 T 59 Cancer Gl7 (3þ4) Sensitive
C18 4 T 73 Cancer Gl8 (3þ5) Sensitive
C19 3 R — Cancer Gl8 (3þ5) Naive
C20 3 R — Cancer Gl8 (3þ5) Naive
C21 7 T 85 Cancer Gl9 (4þ5) Sensitive
C22 4þ5 T 80 Cancer Gl10 (5þ5) Sensitive
Abbreviations: C¼ cystectomy; R¼ radical prostatectomy; T¼ transurethral resection of the prostate.
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keratinocyte growth medium supplemented with EGF, bovine
pituitary extract (Life Technologies Ltd, Paisley, UK), 2 ngml 1
stem cell factor (SCF) (First Link UK Ltd, Wolverhampton, UK),
100 ngml 1 cholera toxin (Sigma-Aldrich Company Ltd,
Gillingham, UK) and 1 ngml 1 granulocyte macrophage colony-
stimulating factor (GM-CSF) (First Link UK Ltd). Cells were
cultured in the presence of irradiated (60Gy) STO (mouse
embryonic fibroblast) cells. After expansion, CD133þ /a2b1inte-
grinhi (stem-like (SC)), CD133 /a2b1integrin
hi (transit-amplifying
(TA)) and a2b1integrin
lo (committed basal (CB)) cells were isolated
by magnetic-activated cell sorting (MACS; Miltenyi Biotec,
Surrey, UK) as described previously (Richardson et al, 2004;
Collins et al, 2005). SC cells are the most primitive cells, with TA
cells being a progenitor population and CB cells being further
along the differentiation hierarchy.
Irradiation of cells. To irradiate cells, an RS2000 X-Ray Biological
Irradiator was used that contains a Comet MXR-165 X-Ray Source
(Rad-Source Technologies Inc., Suwanee, GA, USA). A dose of 2 or
10Gy was administered with a dose rate of 0.02 or 0.08Gy s 1. To
determine colony-forming ability post irradiation, primary cultures
were irradiated as a whole population and subsequently sorted. To
assay DNA damage, in response to radiation, primary cells were
sorted into their respective populations before irradiation because
of the rapid nature of DNA damage formation.
Clonogenic recovery. Primary prostate cultures were irradiated
(2Gy) and immediately sorted into subpopulations (SC, TA and
CB), counted and plated on to 35-mm collagen-coated plates
(BD Biocoat, BD Biosciences, Oxford, UK) at a density of 100 cells
per well in the presence of irradiated STO feeder cells. For treatment
with HDAC inhibitor, cells were treated with 0.6mM of Trichostatin
A (TSA; Sigma-Aldrich Company Ltd, T1952) for 1 h and 30min
and then irradiated (2Gy) and treated as above. Colonies were
subsequently scored if they contained 432 cells (at least 5
population doublings, which are considered as self-sustaining
colonies with proliferation potential (Puck and Marcus, 1956;
Francipane et al, 2008), usuallyB14 days after treatment. Colonies
were visualised by staining with 1% crystal violet/10% ethanol/PBS.
Alkaline and neutral comet assays. Comet assays were modified
from Sturmey et al (2009). Primary prostate epithelial cells were
separated into SC, TA and CB cells, resuspended in 25ml PBS and
irradiated. At 30min post irradiation, 225ml of low-melting-point
(LMP) agarose was added to the cells, mixed and pipetted onto an
agarose-coated slide (1% agarose in PBS). A clean coverslip was
placed on top and slides placed at 4 1C for 15min. Once set,
coverslips were removed and slides placed in lysis buffer (2.5 M NaCl,
1mM EDTA, 10mM Tris, 10% DMSO, 1% Triton X-100, pH 10)
overnight at 4 1C. For the alkaline comet assays, slides were incubated
in alkaline solution (0.3M NaOH, 1mM EDTA, pH 13) for 40min at
4 1C, and then electrophoresed at 23V, 300mA in the same alkaline
solution (for 40min on ice). Subsequently, they were incubated for
2 10min in neutralising buffer (0.4 M Tris, pH 7.5). For the neutral
comet assays, slides were incubated in TBE electrophoresis buffer at
4 1C for 40min and electrophoresed at 25V for 20min. For both
assays SYBRgold was applied (1 : 10 000 in TE buffer, 10mM Tris-Cl,
pH 7.5, 1mM EDTA) to stain the DNA. Comets were measured
using CometScore freeware (TriTek Corp., Sumerduck, VA, USA)
following image capture using a Nikon Eclipse TE300 fluorescent
microscope (Nikon, Surrey, UK) with a  10 lens.
Immunofluorescence. Immunocytochemistry was conducted on
sorted a2b1integrin
hi/CD133þ (SC), a2b1integrin
hi/CD133 (TA)
and a2b1integrin
lo (CB) primary cells. The cell isolates were allowed
to adhere for 2 h onto collagen-coated slides, and in some
experiments were treated with 0.6mM of TSA (Sigma-Aldrich
Company Ltd T1952) for 1 h and 30min and irradiated (2Gy)
before fixing in 2% paraformaldehyde/PBS/0.2% Triton X-100, pH
8.2 (20min), then permeabilised with 0.5% NP40/PBS (20min). Cells
were then blocked (2% BSA/1% normal goat serum/PBS) and
incubated in primary antibody in 3% BSA/PBS at 4 1C overnight
followed by washes in 0.5% BSA/0.175% Tween-20/PBS. Secondary
antibody was added for 45min in 3% BSA/PBS followed by washes.
Slides were mounted with Vectashield with DAPI (Vector Labora-
tories, Peterborough, UK). Primary antibodies used were as follows:
anti-phospho-Histone H2A.X (Ser139), clone JBW301 (Millipore,
Watford, UK); 53BP1 (Alexis Biochemicals, Exeter, UK, ALK-210-
419 or Abcam, Cambridge, UK, ab36823); phospho-Chk2 (Thr68;
Cell Signaling Technology, Hitchin, UK, 2661); phospho-(Ser/Thr)
ATM/ATR substrate antibody (Cell Signaling Technology 2851);
H3K9me3 (histone H3(trimethylated at lysine 9); Diagenode,
Denville, NJ, USA, pAb-056-050); Ki67 (Abcam ab15580); H3K27me3
(histone H3(trimethylated at lysine 27); Millipore 17-622).
Secondary antibodies were goat anti-mouse AlexaFluor-488 (Life
Technologies Ltd A11029) and goat anti-rabbit AlexaFluor-568
(Life Technologies Ltd A11036).
Confocal images were acquired on Zeiss LSM 510 and Zeiss LSM
Meta Laser confocal microscopes (Zeiss, Cambridge, UK). Coloca-
lisation analysis, Pearson’s correlation, line scan analysis and
fluorescence intensity measurements were carried out using Volocity
software (Improvision, Perkin Elmer, Waltham, MA, USA). For foci
counting, images were captured using a Nikon Eclipse TE300
fluorescent microscope (Nikon, Surrey, UK) with a  63 oil
immersion lens and foci were counted using the multi-point tool
in ImageJ software (Town of Mount Royal, QC, Canada).
Flow cytometry. Primary cultures were trypsinised, resuspended
in MACs buffer and incubated with antibodies to the a2 subunit of
integrin a2b1 (CD49b-RPE, MCA743PET, AbD Serotec, Kidlington,
UK) and CD133/2 (293C)-APC (130-090-854, Miltenyi Biotec) for
10min at 4 1C.
For the detection of heterochromatin, the cells were then
permeabilised in MACs buffer with 0.5% W/V saponin and 20%
normal goat serum (NGS) and then incubated with the H3K9me3
antibody (Diagenode) or H3K27me3 antibody (Millipore 17-622)
in MACs buffer with 20% NGS. Cells were then washed and
incubated with goat anti-rabbit AlexaFluor-488 secondary
antibody (Life Technologies Ltd) in MACs buffer with 20% NGS.
Finally, cells were analysed on a CyAn-ADP flow cytometer
(Beckman Coulter, High Wycombe, UK) and data processed using
Summit v4.3 software (Beckman Coulter).
Statistical analysis. Median values of each analysis were calcu-
lated. Significance was assessed using the Wilcoxon rank-sum test
or t-test for smaller sample numbers where stated (GraphPad
Prism, La Jolla, CA, USA). The P-values indicating statistical
significance are displayed.
RESULTS
SCs are more radioresistant than progenitor cells. To establish
whether prostate SCs are more resistant to irradiation than
progenitors, we determined the potential of each population to
initiate colonies (at clonal density) following irradiation. Our
rationale for using 2Gy was to mimic the clinical daily dose of 2Gy
that has been routinely administered to patients (Bromfield et al,
2003). Primary cells, derived from patients with BPH, and prostate
cancer, including those who had undergone androgen-ablation
therapy, were irradiated, sorted into SCs and progenitors (TA and
CB) and plated to determine colony-forming efficiency (CFE)
that is represented as surviving fraction (SF) after 2Gy (SF2Gy;
Figure 1A and B). The highest SF2Gy (post irradiation) was
observed in the SCs, independent of disease status (Figure 1A and B).
To investigate the consequences of irradiation on each cell
type, DNA damage was measured following radiation in each
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Figure 1. Stem-like cells (SCs) from benign and cancer cultures are less radiosensitive and have a differential DNA damage response compared
to progenitor TA cells and more differentiated CB cells. (A and B) Benign and malignant primary prostate epithelial cultures were treated with
2 Gy radiation and cell populations sorted and plated for clonogenic assays. Surviving fraction following 2 Gy (SF2Gy) was calculated and plotted
for each cell subpopulation. Each symbol represents a different patient sample (red symbols indicate prostate cancer and blue symbols indicate
BPH) and the black bar represents the median. (C and D) Benign and malignant primary prostate epithelial cultures were sorted into cell
subpopulations and treated with 2 Gy radiation, and then processed in alkaline (C) and neutral (D) comet assays. Each symbol represents a different
patient sample (red symbols indicate prostate cancer and blue symbols indicate BPH) and the black bar represents the median. Statistical
significance values were measured using the Wilcoxon rank-sum test (*Po0.05, **Po0.01, ***Po0.001).
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population (Figure 1C and D). To do this we used comet assays to
measure DNA damage directly, following radiation doses of 2 and
10Gy. Alkaline comet assays were used to measure single-strand
breaks (SSBs), double-strand breaks (DSBs), alkali labile sites,
DNA crosslinks and incomplete excision repair (Singh et al, 1988;
Tice et al, 2000; Nandhakumar et al, 2011; Swain and Subba Rao,
2011). We observed comparable damage in each population, with a
clear dose-dependent increase (up to 10Gy; Figure 1C). In contrast,
using the neutral comet assay, we observed that the SCs incurred
significantly less damage than either the TA or CB populations
(Figure 1D). Moreover, there was no significant difference in DNA
damage with increasing dose. The neutral comet assay has a bias for
measuring lethal DSBs (Ostling and Johanson, 1984; Singh et al,
1988; Lemay and Wood, 1999; Wojewodzka et al, 2002; Van Kooij
et al, 2004; Swain and Subba Rao, 2011). This suggests that the SCs
are protected from this specific type of damage compared with the
progenitor (TA) and more differentiated (CB) cells. As observed
with the colony-forming assay, this effect on DNA damage was
independent of disease status.
SCs sustain less DSBs than progenitors. To confirm this finding,
we investigated the DSB DNA damage response further. Primary
cells were sorted, irradiated and fixed at 30min post irradiation. Cells
were then stained for gH2AX and 53BP1 DNA damage nuclear foci,
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Figure 2. Fewer SCs from benign and malignant primary epithelial cultures contain DNA damage foci relative to TA and CB cells post irradiation.
(A) Cells from benign and malignant primary prostate epithelial cultures were sorted then fixed and stained for gH2AX and 53BP1 at 30 min
post irradiation. Representative images are shown of nuclei showing (i) negative (ii) and positive staining for DNA damage foci (gH2AX (green),
53BP1 (red) and DAPI nuclear staining (blue)). Image squares containing a single nucleus measured 27.35mm by 27.35mm. (B–E) Cell nuclei were
scored for foci and B100 nuclei per sample were counted. The graphs indicate the percentage of cell nuclei containing foci. Each symbol
represents a different patient sample (red symbols indicate prostate cancer and blue symbols indicate BPH). Boxplots show minimum, 25%,
median, 75% and maximum. Statistical significance values were measured using the Wilcoxon rank-sum test (**Po0.01, ***Po0.001).
Radiosensitivity of prostate stem-like cells BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.691 3027
indicative of DSBs (Paull et al, 2000; Belyaev, 2010; Mah et al, 2010)
(Figure 2A). Approximately 90% of TA and CB cell nuclei showed
evidence of DSBs, whereas significantly fewer (30–50%) SCs
sustained DSBs (Figure 2B–E). These results are in agreement with
our findings using the neutral comet assay, showing evidence of DSBs
in the majority of TA and CB cells, but only in a minority of SCs.
We also investigated the downstream events following induction
of DNA damage by staining the cell populations for members of
the ATM-Chk2 DSB DNA damage pathway (Figure 3). Again, we
observed that the percentage of SCs containing ATM/ATR
phosphorylated substrates and phospho-Chk2Thr68 was signifi-
cantly less than either of the progenitor populations, again
reinforcing our findings that SCs sustain less DSBs.
Although the majority of SCs appear to sustain no damage, we
wanted to know if the minority subpopulation that did sustain
damage could undertake DNA repair. To do this, the number of
foci per cell nucleus was quantified. It was clear that in all cell types
(SC, TA, CB), and in all patients, DNA repair was taking place, as
evidenced by a significant reduction in the number of foci per cell
nucleus at 24 h compared with 30min (Figure 4).
SCs are less proliferative and have increased heterochromatin.
As SCs appeared to sustain less DNA damage following irradiation,
we hypothesised that they may have an inherent protection
mechanism. We had previously demonstrated that the SCs are less
proliferative (Lang et al, 2010), and hence we quantified the number
of cells expressing the proliferation marker Ki67 (Figure 5A). Primary
cells from six patients were sorted as previously described and stained
with an antibody against Ki67. We found that the percentage of SCs
expressing Ki67 was significantly less than either the TA or CB cells,
suggesting that the progenitor (TA) and more differentiated (CB) cells
are more proliferative than the SCs (Figure 5A).
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Figure 3. Fewer prostate SCs from benign and malignant primary epithelial cultures have an active ATM/Chk2 DNA damage response post
irradiation. Nuclear DNA damage foci were scored as in Figure 2, after staining with ATM/ATR substrate antibody (A) and pChk2Th68 antibody (B).
Percentage of cell nuclei that contain foci is represented. Each symbol represents a different patient sample (red symbols indicate prostate
cancer and blue symbols indicate BPH). Representative images of nuclei showing co-staining of gH2AX antibody (green), (Ai) ATM/ATR substrate
antibody or (Bi) pChk2Th68 antibodies (red) and DAPI nuclear stain (blue) are shown. Boxplots show minimum, 25%, median, 75% and maximum.
Statistical significance values were measured using the Wilcoxon rank-sum test (*Po0.05, **Po0.01).
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One other mechanism by which a cell could sustain less damage
is by packing more DNA into heterochromatin. Storch et al (2010)
found that growing cells in a 3D formation led to increased
chromatin condensation, which subsequently resulted in radio-
resistance. Furthermore, when measuring the number of DSBs in
euchromatin vs heterochromatin in monolayer cells, the authors
found a ratio of 2 : 1, that is, fewer breaks in heterochromatin.
When we examined heterochromatin marks (H3K27me3 and
H3K9me3) in each cell population, we observed that a proportion
of SCs appeared to have increased heterochromatin content
compared with the other cell types (TA and CB) (Figure 5B).
We quantified heterochromatin by measuring the fluorescence
intensity of sorted cells (Figure 5C) as well as flow cytometry where
cells were co-stained with CD49b (a2b1integrin) and CD133 to
distinguish the three populations (Figure 5D). This showed that
SCs had significantly increased heterochromatin compared with
the progenitor (TA) and more differentiated (CB ) cells.
To confirm that heterochromatin conferred a protective effect to
the cells, we carried out dual staining of DNA damage foci and
heterochromatin that showed preferential formation of foci located
almost exclusively at nuclear sites devoid of heterochromatin
staining (Figure 5Ei). In addition, several SCs were observed to
have high levels of heterochromatin throughout the nucleus that
corresponded with an absence of foci (Figure 5Eii).
Combination treatment of HDAC inhibitor and radiation
results in increased DNA damage and reduced clonogenic
survival in the SCs. Based on the heterochromatic patterns, we
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Figure 4. All cell types are equally capable of undergoing DNA repair post irradiation. Number of foci per cell nucleus were counted at 30 min
and 24 h post irradiation in SCs (A), TA (B) and CB (C) cells. Each symbol represents a single cell (red symbols indicate prostate cancer and blue
symbols indicate BPH). Boxplots show minimum, 25%, median, 75% and maximum. Statistical significance values were measured using the
Wilcoxon rank-sum test (*Po0.05, **Po0.01, ***Po0.001).
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hypothesised that manipulating chromatin status in the SCs would
render them more sensitive to radiation treatment. To achieve this,
cells were sorted and treated with a low dose of HDAC inhibitor
(0.6 mM TSA) for 1 h and 30min followed by 2Gy irradiation. The
treated cells were then fixed 30min post irradiation and
subsequently stained for DNA damage foci (Figure 6A). The effect
of TSA was confirmed by western blot using lysates from unsorted
cells for acetylated histones where we observed an increase in
histone acetylation following treatment (Figure 6B). This is known
to correlate with chromatin decondensation (Toth et al, 2004).
Following the combination treatment, the number of SCs
sustaining DSBs, as evidenced by increased number of cells
containing foci, significantly increased (Figure 6Ai). There was no
significant increase in the percentage of TA or CB cells containing
foci as the majority of these cells contain foci following radiation
alone, and hence the effect is already saturated. On quantifying foci
number in the SCs we found no increase in number of foci per cell
nucleus following TSA treatment (Figure 6Aii). We then assessed
the effect of combination treatment on clonogenic recovery and
found that the SCs formed significantly fewer colonies following
combination treatment compared with irradiation alone
(Figure 6C). We concluded from this experiment that the HDAC
inhibitor had sensitised the SCs to radiation treatment.
DISCUSSION
In this study, we present evidence demonstrating that primitive
prostate SCs, from freshly cultured patient tissues, are more
radioresistant than more differentiated cells, which we show to be
independent of patient disease status. We propose that the SCs, by
having higher levels of heterochromatin, sustain fewer lethal DSBs,
which contributes to increased survival. Significantly, by treating
this population with an HDAC inhibitor, DNA damage was
increased, resulting in sensitisation of the cells to radiation, thus
reducing survival.
Using colony-forming assays, we were able to demonstrate that
SCs were less affected by irradiation as compared with the
progenitor cells. Although the overall induction of DNA damage
was similar between populations (alkaline comet assays), we
observed a significant reduction in the percentage of SCs sustaining
lethal DSBs (neutral comet assays and DNA damage foci). Lack of
activation of the ATM/ATR DNA damage signaling pathways
correlated with this population. By quantifying the number of foci
in the minority of SCs positive for foci, as well as TA and CB cells,
we confirmed that DNA repair was undertaken in all cell types.
We present evidence here that SCs sustain less DNA damage
because of increased heterochromatin content. Our results pointed
towards the use of HDAC inhibitors, in combination with
radiation, as a therapy for prostate cancer. HDAC inhibitors have
been heavily investigated for their clinical use and are also in
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Figure 6. Treatment with an HDAC inhibitor radiosensitises stem cells
from benign and malignant primary epithelial cultures (Ai) Stem-like
cells (SCs), TA and CB cells were treated with 0.6mM TSA for 90 min,
irradiated (2 Gy) and then fixed 30 min post IR and stained for gH2AX.
Each symbol represents a different patient sample (red symbols
indicate prostate cancer and blue symbols indicate BPH) and the black
bar represents the median. (Aii) Number of foci per cell nucleus of SCs,
following irradiation or TSA plus irradiation. (B) Western blot for
acetyl-H3 in unsorted cell lysates following treatment with 0.6mM
TSA for 2 h. (C) Whole populations of primary epithelial cell cultures
were treated with 0.6mM TSA for 90 min, irradiated (2 Gy) and sorted
into subpopulations 30 min post IR. Surviving fraction following 2 Gy
(SF2Gy) and surviving fraction following TSA treatment and 2Gy
(SF-TSA-2Gy) were calculated and plotted for SCs following clonogenic
assays. Each symbol represents a different patient sample (red symbols
indicate prostate cancer and blue symbols indicate BPH), Boxplots
show minimum, 25%, median, 75% and maximum. Statistical
significance values were measured using the Wilcoxon rank-sum test
(*Po0.05).
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clinical trials for prostate cancer (Marchion and Munster, 2007;
Frew et al, 2009; Atadja, 2011). There are encouraging results with
HDAC inhibitors targeting proliferating and nonproliferating cells
(Burgess et al, 2004). However, they are often being employed as
toxins, rather than response modifiers, the latter being what we
propose based on the data in Figure 6. Our work shows that a short
exposure to sublethal doses of HDAC inhibitors may be enough to
sensitise prostate SCs.
It is also possible that less damage is sustained because of the
less proliferative nature of SCs. It has previously been shown that
adult SCs are predominantly quiescent and that this can reduce
accumulation of mutations through DNA replication and contribute
to therapy resistance (Mohrin et al, 2010; Blanpain et al, 2011;
Li and Bhatia, 2011). Using the vital dye PKH26, we were able to
show that prostate stem cells undergo up to four population
doublings (in monolayer culture) before exiting the cell cycle
(Lang et al, 2010). We also observed here that significantly more
progenitor and more differentiated cells (TA and CB cells) are in
cycle compared with the SCs.
In summary, radiorecurrent prostate cancer is a significant
problem for both physicians and patients because of local and
systemic resistance (Ishkanian et al, 2010). The heterogeneity of
prostate cancers has been well documented, yet we are the first to
report the radiation-resistant phenotype of the primitive SCs and
the mechanism behind this resistance. Other radiation resistance
mechanisms have been documented, such as increased scavenging
of reactive oxygen species (ROS) in breast cancer stem cells and
increased efficiency of DNA repair and DNA damage response in
glioblastoma cancer stem cells (Bao et al, 2006; Woodward and
Bristow, 2009; Diehn et al, 2009a). It remains to be seen whether
those play an additional role in radiation resistance of prostate
tumours.
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